CLINICAL TRIALS PROFILE FOR METOLAZONE
✉ Email this page to a colleague
All Clinical Trials for metolazone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00649051 ↗ | Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions. |
| NCT00649181 ↗ | Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-10-01 | The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose administration under fasting conditions. |
| NCT00650195 ↗ | Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2004-02-01 | The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for metolazone
Condition Name
Clinical Trial Locations for metolazone
Trials by Country
Clinical Trial Progress for metolazone
Clinical Trial Phase
Clinical Trial Sponsors for metolazone
Sponsor Name
